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Current therapeutic interventions for the treatment of respiratory
infections are hampered by the evolution of multidrug resistance
in pathogens as well as the lack of effective cellular targets.
Despite the identification of multiple region-specific lung pro-
genitor cells, the identity of molecules that might be therapeuti-
cally targeted in response to infections to promote activation of
progenitor cell types remains elusive. Here, we report that loss of
Abl1 specifically in SCGB1A1-expressing cells leads to a significant
increase in the proliferation and differentiation of bronchiolar ep-
ithelial cells, resulting in dramatic expansion of an SCGB1A1+ air-
way cell population that coexpresses SPC, a marker for type II
alveolar cells that promotes alveolar regeneration following bac-
terial pneumonia. Furthermore, treatment with an Abl-specific al-
losteric inhibitor enhanced regeneration of the alveolar epithelium
and promoted accelerated recovery of mice following pneumonia.
These data reveal a potential actionable target that may be
exploited for efficient recovery after pathogen-induced infections.
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Damage to the lung epithelium in response to pathogens is amajor health problem worldwide. Parenchymal lung infections
disrupt lung epithelial architecture and function by eliciting de-
struction of airway and alveolar cell populations (1–6). Approxi-
mately 50,000 cases of lung infection by Staphylococcus aureus occur
per year in the United States (7). S. aureus pneumonia has high
morbidity and mortality rates, as it frequently presents in the con-
text of hospital-acquired pneumonia and patients frequently prog-
ress to sepsis and multiorgan system failure (8–10). Currently, there
are no approved drugs that directly prevent or repair epithelial
cell damage following pathogen-induced lung injury. Therapeutic
strategies to protect or promote lung epithelial cell regeneration
following injury could profoundly improve patient outcomes when
used in combination with antibiotics and supportive care, particu-
larly in the context of infections caused by resistant bacterial strains.
Lung epithelial cells are the first line of defense against foreign
agents such as pathogens and chemicals. The lung epithelium is
composed of airway and alveolar cells. In the airway epithelium,
elegant studies have identified both basal and secretory cells as
critical cell types for regeneration during normal cell turnover and
following injury (11–15). In the alveoli, type II alveolar epithelial
cells (AECs) give rise to type I AECs during regeneration fol-
lowing injury (16). Other reports have implicated a small sub-
population of cells at the bronchioalveolar duct junction (BADJ)
expressing markers of both secretory cells (SCGB1A1+) from the
airway and type II AECs (SPC+, expressed by Sftpc) as progenitor
cells for epithelial cells in both the distal airway and alveoli (17).
However, at baseline, the contribution of this putative “bron-
chioalveolar stem cell” population is small, with on average <1 cell
per BADJ (11). Targeting pathways that promote expansion of
these or other progenitor cells after lung injury would ameliorate
the morbidity and mortality associated with pneumonia and other
conditions that cause lung damage.
Here we uncover a previously unknown role for the Abelson
(Abl) kinases in regulating the regeneration response of the lung
epithelium after pathogen-induced injury. The Abl kinases Abl1
and Abl2 are a family of nonreceptor tyrosine kinases that regu-
late a wide variety of cellular processes during development and
normal homeostasis (18–21), but can have deleterious effects on
cell survival, proliferation, and cell–cell junction adhesion upon
their up-regulation following inflammation, tumorigenesis, and
oxidative stress (22–28). We and others have previously identified
a role for the Abl kinases in the integrity of the endothelium in the
context of vascular leak syndrome (29–34). However, therapies
focused on preventing vascular leak have not translated to viable
therapeutic approaches for the treatment of acute lung injury in
clinical trials (35). Here we report that genetic and pharmaco-
logical inactivation of Abl kinases mobilizes secretory cells from
the distal airway and BADJ to promote the expansion of double-
positive SCGB1A1+ SPC+ cells within 4 to 24 h after injury,
leading to enhanced regeneration of the damaged alveolar epi-
thelium following bacterial infection induced by live S. aureus or
Streptococcus pneumoniae. These findings suggest that available
Abl kinase-specific inhibitors, which have been used for treating
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leukemia, might be repurposed to treat the damaged lung following
pathogen exposure.
Results
Abl Kinases Are Up-Regulated in Lung Epithelial Cells Following Injury.
To evaluate whether Abl kinases play a role in lung epithelial cell
integrity during regeneration and/or repair, we first assessed Abl
expression in primary human bronchial epithelial cells (HBECs)
grown in air–liquid interface (ALI) cultures before and after
pathogen-induced injury. HBECs were grown in ALI cultures for
28 d to induce differentiation of basal cells to a pseudostratified
layer of basal, secretory, and ciliated epithelial cells (36). At day
28, HBECs were incubated with S. aureus and then harvested
1 and 5 d after bacterial inoculation to evaluate Abl kinase RNA
and protein expression (SI Appendix, Fig. S1A). We observed a 20-
to 30-fold increase in Abl1, and to a lesser extent Abl2, transcripts
at 24 h that persisted up to 5 d following exposure to bacteria (SI
Appendix, Fig. S1B). Abl protein expression was similarly en-
hanced after pathogen exposure (SI Appendix, Fig. S1C). Previous
reports have shown that enhanced Abl kinase activity is associated
with a wide variety of pathologies, including endothelial barrier
dysfunction, tumorigenesis, and inflammation (19). Thus, Abl ki-
nase inhibition may affect the response of lung epithelial cells
during injury, regeneration, and/or repair.
Loss of Abl1 in SCGB1A1+ Lung Epithelial Cells Promotes Accelerated
Recovery in a Mouse Model of Pneumonia. To evaluate whether Abl
has a role in regulating the response of bronchial epithelial cells
to injury in vivo, we generated a conditional, secretory cell-type
specific knockout of Abl1 with concomitant expression of a far-
nesylated GFP (i.e., membrane-bound GFP) reporter [CC10
(Scgb1a1)-CreERT; Rosa26-fGFP; Abl1fl/fl] upon administration
of tamoxifen. We obtained efficient (>75%) excision of Abl1 in
Scgb1a1-expressing epithelial cells following i.p. delivery of four
doses of tamoxifen 2 wk before inducing injury (37). Scgb1a1, also
known as CC10 or CCSP, is widely used as a marker of secretory
cells in mammalian lung airways. To injure the lung epithelium,
we employed a mouse model of pneumonia induced by intranasal
insufflation of 5 × 108 cfu S. aureus (38) (SI Appendix, Fig. S1D).
In this model, mice survive the bacterial infection despite signifi-
cant lung injury accompanied by inflammation and edema. Fol-
lowing infection with S. aureus, we observed a >10-fold increase in
Abl1 expression in isolated GFP+ (Scgb1a1 driver) cells in wild-
type mice that was abrogated in Abl1fl/fl mice (SI Appendix,
Fig. S1E). Abl1fl/fl mice displayed remarkable recovery from
symptoms of infection compared with wild-type mice (Fig. 1 A–C).
Abl1fl/fl mice were active and lacked pathological signs of infection
displayed by wild-type mice after S. aureus inoculation (a 30-s video
corresponding to Fig. 1B is in Movie S1; a 2-min tracing of mouse
movement is in Fig. 1C). Bronchioalveolar lavage (BAL) samples
from mouse lungs 3 d after exposure to S. aureus showed a sig-
nificant decrease in protein (Fig. 1D), the cell-damage marker
LDH (Fig. 1E), and leukocytes (SI Appendix, Fig. S2) in Abl1fl/fl
compared with wild-type mice. Abl1 knockout mice also exhibited
significantly diminished injury in lung tissue sections 72 h after
injury (Fig. 1 F and G). Similar results were observed in Abl1fl/fl
mice treated with an adenoviral vector encoding a CC10 (Scgb1a1)
promoter driving the expression of Cre-recombinase (Ad5-CC10-
Cre) to induce excision of the floxed locus in the Abl1fl/fl mouse
(SI Appendix, Fig. S3). Of note, all wild-type mice shown were
treated with tamoxifen, and evaluation of tamoxifen-treated
wild-type mice versus untreated wild-type mice showed no
significant differences in the degree of lung injury.
Given the reduction in immune cell infiltration in the alveolar
space detected in BAL fluid (SI Appendix, Fig. S2), we next
evaluated whether loss of Abl1 in Scgb1a1-expressing epithelial
cells could affect the immune response to S. aureus infection. We
evaluated whether the observed decrease in immune cell in-
filtration in the BAL fluid of Abl1 knockout mice was specific to
the alveolar space or whether there was also a decrease in the
influx of immune cells into the lung parenchyma. Analysis of H&E
sections of lungs from wild-type and Abl1 knockout mice sug-
gested that the reduction in immune cell infiltration was specific
to the alveolar space, as a neutrophilic infiltration was observed
in the lung parenchyma of both wild-type and Abl1 knockout
mice (SI Appendix, Fig. S2B). Fluorescence-activated cell sorting
(FACS) analysis of the BAL fluid showed a decrease in the total
immune cell (CD45+) and neutrophil populations (Ly6G+) in the
alveolar space, without changes in the proportion of neutrophils in
the BAL fluid of Abl1 knockout compared with wild-type mice (SI
Appendix, Fig. S2 E–H). Moreover, we found no changes in the
populations of immune cells, including neutrophils in the whole
lung (non-BAL fluid component) of wild-type and Abl1 knockout
mice after injury (SI Appendix, Fig. S4 C–F). The finding that loss
of Abl1 in Scgb1a1+ cells leads to a decrease in leukocytes in the
alveolar space only (BAL fluid component) without changing the
total immune cell population in the lung (non-BAL fluid com-
ponent) suggested that loss of Abl1 in Scgb1a1+ epithelial cells
protects and/or promotes regeneration of epithelial barrier function
following injury, thereby reducing protein and cellular infiltration
Fig. 1. Inactivation of Abl1 in Scgb1a1+ lung epithelial cells protects mice
from S. aureus-induced lung injury. (A) Timeline of experiment: Two weeks
before nasal insufflation of 5 × 108 cfu S. aureus, both wild-type and
Abl1fl/fl mice were treated with tamoxifen in CC10 (Scgb1a1)-CreERT2 mice.
(B) Screenshot of Movie S1 of wild-type and knockout mice 24 h after nasal
insufflation of S. aureus. (C) Two-minute tracing of mice performed with
Adobe Premiere Pro showing a dramatic increase in mouse movement in
knockout compared with wild-type mice. (D and E) Bronchioalveolar lavage
showing reduced protein (D) and LDH (E) in knockout mice compared with wild-
type mice. (F) H&E staining 3 d following nasal insufflation of S. aureus in wild-
type and knockout mice showing increased protein and cell infiltrates in the
airspace of wild-type mice compared with knockout mice. (A composite of im-
ages of mouse left lung sections using a 10× objective on the Zeiss AxioImager
microscope stitched together with Zen software to recreate the entire left lung.)
(G) Quantification of alveolar space infiltrates on H&E sections of wild-type vs.
knockoutmice normalized to a healthy, noninfectedmouse. Graphs depict means
and SEM of “n” mice, where n represents each individual animal used
(i.e., n = 37 represents 37 individual mice). *P < 0.05, **P < 0.01, and ***P < 0.001.





















into the alveolar space, which enhances gas exchange compared
with wild-type mice.
To assess whether loss of Abl1 in the lung epithelium has a
protective effect by blocking pathogen infection, we evaluated
whether loss of Abl1 in Scgb1a1+ cells confers differential sus-
ceptibility of lung epithelial cells to bacterial infection compared
with wild-type mice. We found no significant change in bacterial
load in either the alveolar space (BAL fluid component) or the
whole lung (non-BAL fluid component) 24 and 72 h after injury
(SI Appendix, Fig. S4 A and B). We also found no significant
change in cytokine production levels in the BAL fluid 24 and
72 h after injury (SI Appendix, Fig. S2 C and D).
The finding that genetic inactivation of Abl1 in Scgb1a1+ cells
promotes recovery from pathogen-induced lung injury in a mouse
model of pneumonia without modulating susceptibility to bacterial
infection or immune responses suggests that Abl kinases modulate
the regeneration response of lung epithelial cells following injury.
Genetic Inactivation of Abl1 in SCGB1A1+ Lung Epithelial Cells
Promotes Regeneration of the Alveolar Epithelium After Pathogen-
Induced Lung Injury. To dissect the cellular effects of Abl kinase
inactivation in lung epithelial cells that could explain the en-
hanced recovery observed following bacterial infection, CC10
(Scgb1a1)-CreERT; Rosa26-fGFP; Abl1fl/fl and the corresponding
wild-type, control mice were killed at various times following
nasal insufflation of S. aureus. Staining for lung epithelial cell
populations (Fig. 2A) revealed that damage following nasal in-
sufflation of S. aureus occurred primarily in type I alveolar epi-
thelial cells, identified by immunostaining for the cell-surface
marker RAGE (also known as AGER), without significant changes
in the number of type II AECs (SPC+) and airway epithelial cell
types in regions of lung injury (Fig. 2B). Damage to type I AECs is
maximal at 24 to 72 h following S. aureus exposure, with wild-type
mice achieving complete recovery by day 6 (Fig. 2C, Top). In
contrast to wild-type mice, the alveolar epithelium of Abl1fl/fl mice
exhibited complete recovery by day 3 postinfection (Fig. 2C, Bot-
tom; quantification in Fig. 2D). These findings were surprising
because Abl1 was inactivated specifically in Scgb1a1-expressing
cells of the airway, and type I AECs do not express Scgb1a1.
To distinguish between protective and regenerative effects of
Abl kinase inhibition, we evaluated lung tissue isolated at earlier
time points after S. aureus exposure and assessed these sections for
lung epithelial cell damage. At 4 h following nasal insufflation of
S. aureus, type I AEC damage, as measured by alveolar volumes,
was observed in both wild-type and Abl1 knockout mice (Fig. 2 C
and D). These findings suggest that inactivation of Abl signaling in
Fig. 2. Genetic inactivation of Abl1 promotes re-
generation of the alveolar epithelium following
nasal insufflation of S. aureus. (A) Schematic of distal
lung epithelial cell populations in the bronchial tree.
(B) CC10 (Scgb1a1)-CreER; Rosa26-fGFP; Abl1wt or
Abl1fl/fl mice were given tamoxifen four times 2 wk
before nasal insufflation of S. aureus to induce ex-
cision of Abl1 and/or expression of GFP in Scgb1a1+
cells. Panel of immunofluorescence stains for RAGE
(type I alveolar epithelial cell marker), SPC (type II
alveolar epithelial cell marker), and Hoechst 33342
(nuclear stain) shows that type I alveolar epithelial
cells are the most common site of injury (yellow
dotted lines) following exposure to S. aureus in wild-
type mice for 3 d. (Scale bar, 100 μm.) (C) Immuno-
fluorescence staining for the type I cell marker RAGE
4 h, 3 d, and 6 d following nasal insufflation of
S. aureus shows widespread damage (loss of RAGE
expression and reduced alveolar volume) to the al-
veolar epithelium in wild-type (WT) mice that peaks
at 3 d and resolves in 1 wk compared with damage in
Abl1fl/fl (KO) mice at 4 h that completely resolves by
day 3. (Scale bars, 50 μm.) (D) Quantification show-
ing reduced damage (as measured by loss of alveolar
area/volume calculated across an entire section of
the left lung compared with uninfected mice) in
Abl1fl/fl mice compared with wild-type mice 3 d after
injury. Graphs depict means and SEM of n mice,
where n represents each individual animal used (i.e.,
n = 6 represents six individual mice). ***P < 0.001;
ns, not significant.




























SCGB1A1+ cells fails to prevent pathogen-induced alveolar injury
but rather promotes rapid regeneration of type I AECs, leading to
accelerated recovery of Abl1fl/fl mice following pathogen exposure.
Conditional Deletion of Abl1 Promotes Expansion of Double-Positive
SCGB1A1+ SPC+ Cell Population Following Injury.To dissect the role
of Abl1 in Scgb1a1+ cells in the regeneration of the damaged al-
veolar epithelium following pathogen exposure, we performed
lineage tracing experiments of the Scgb1a1+ cell population using a
Rosa26-fGFP reporter in CC10 (Scgb1a1)-CreERT mice. We de-
tected a dramatic increase in the number of GFP+ (Scgb1a1 driver)
cells in the lung parenchyma of Abl1fl/fl mice compared with wild-
type mice 72 h after injury (Fig. 3A and SI Appendix, Fig. S5A).
Staining for the type II AEC marker surfactant protein C (SPC),
encoded by Sftpc, revealed that the GFP+ cells in the alveolar space
coexpress SPC (Fig. 3B). Following injury, we observed a twofold
increase in the number of GFP+ SPC+ cells in Abl1 knockout
compared with wild-type mice. Notably, by day 3 after injury, 30%
of SPC+ cells in Abl1fl/fl mice were GFP+, and therefore lineage-
derived from Scgb1a1-expressing cells (SI Appendix, Fig. S5B;
quantification is in Fig. 3C). Importantly, there was no significant
difference in the GFP+ SPC+ cell populations in uninfected wild-
type versus Abl1fl/fl mice, 3 wk and up to 4 mo after delivery of
tamoxifen to induce Abl1 excision (SI Appendix, Fig. S6).
We sought to investigate whether the GFP+ (Scgb1a1 driver)
SPC+ cells in the alveolar epithelium retained expression of
Scgb1a1. Costaining for GFP and Scgb1a1 showed that GFP+
cells in close proximity to the BADJ retained high levels of
Scgb1a1 protein, but the expression of Scgb1a1 progressively de-
creased in GFP+ cells localized more distally from the BADJ (SI
Appendix, Fig. S5C). Henceforth, we will refer to this population
of cells as double-positive SCGB1A1+ SPC+ cells, even though
they demonstrate variable expression of Scgb1a1 and are likely to
undergo differentiation as they expand farther away from the
BADJ. These data suggest that inactivation of Abl1 in Scgb1a1-
expressing cells greatly enhances a population of double-positive
SCGB1A1+ SPC+ cells in response to injury, and that these cells
appear to originate from the bronchioles and/or BADJ and then
expand into the alveolar epithelium to promote regeneration.
Pharmacological Inhibition of Abl Kinase Promotes Recovery of Mice
Following Pneumonia. The availability of pharmacological inhibi-
tors of the Abl kinases prompted us to evaluate whether treatment
with these compounds might be a useful therapeutic strategy fol-
lowing S. aureus-induced lung infection. We employed the Abl
kinase-specific allosteric inhibitor GNF5 to evaluate Abl kinase
inhibition as a treatment modality in bacterial pneumonia. GNF5
binds specifically to the myristoyl-binding site in the kinase domain
of the Abl kinases and does not inhibit other protein kinases (39).
Administration of GNF5 by oral gavage twice daily (b.i.d.) results
in specific inhibition of the Abl kinases without known off-target
effects (39). Treatment was initiated 1 h after nasal insufflation of
S. aureus, and mice were evaluated 24 and 72 h following injury
(Fig. 4A). Remarkably, two doses of GNF5, one initiated 1 h and
another 16 h after injury, were sufficient to promote recovery after
24 h in drug-treated mice compared with vehicle control-treated
mice (a 30-s video corresponding to movement tracings in Fig. 4B
can be found in Movie S2). In contrast to the immobile and sickly
appearance of vehicle control-treated mice, the mice treated with
GNF5 were active and exhibited a healthy appearance. Analysis of
lung tissue sections at 72 h postinfection revealed a significant
decrease in lung injury in the treated mice (Fig. 4 C and D).
To evaluate the effect of delayed drug treatment that more
closely represents the delay in treatment initiation following the
onset of pneumonia symptoms in the clinical setting, treatment
schedules were initiated for mice exposed to S. aureus 24 h after
injury and compared with mice treated 24 h prior to injury. BAL
samples obtained at day 3 postinfection demonstrated a signifi-
cant reduction in protein concentration in both the pretreatment
group and in mice treated with GNF5 starting at 24 h after injury
(Fig. 4E). Thus, even delayed treatment confers a therapeutic
effect. A significant reduction in lung injury was also observed in
mice treated with the ATP-binding site Abl kinase inhibitor
nilotinib, a Food and Drug Administration (FDA)-approved
drug for treatment of chronic myelogenous leukemia driven by
oncogenic BCR-ABL (Fig. 4F).
Notably, we found a significant increase in the proportion of
GFP+ (Scgb1a1 driver) SPC+ cells in GNF5-treated mice versus
vehicle-treated mice, as well as enhanced SPC expression in
SCGB1A1+ cells within the bronchioles of GNF5-treated mice
after injury (Fig. 4 G–I). Further, the alveolar epithelium in mice
treated with GNF5 recovered more rapidly by day 3 post-
infection compared with control mice (Fig. 4J). These findings
show that pharmacological or genetic inactivation of Abl elicits
an expansion of double-positive GFP+ (Scgb1a1 driver) SPC+
cells that promote rapid regeneration of the alveolar epithelium
following injury.
Fig. 3. Conditional deletion of Abl1 promotes expansion of the GFP+ (Scgb1a1
driver) SPC+ cell population in mouse lungs following injury. (A) CC10 (Scgb1a1)-
CreER; Rosa26-fGFP; Abl1wt (Left) or Abl1fl/fl (Right) mice were given tamoxifen
four times 2 wk before nasal insufflation of S. aureus to induce excision of Abl1
and/or expression of GFP in Scgb1a1+ cells. Three days after exposure to the live
bacteria, knockout mouse lungs demonstrated a dramatic increase in the GFP+
cell population in the alveolar space extending out from the bronchioles (Br) and
BADJ. (Scale bars, 70 μm.) (B) Magnified subset at the 72-h time point (A, white
box) with costaining for GFP and SPC antibodies shows that the GFP+ cell
population in the alveolar space expresses the type II alveolar epithelial cell
marker SPC. (Scale bars, 20 μm.) (C) Quantification of the percent of SPC+ cells
expressing GFP in the entire left lungs of mice infected with S. aureus shows a
doubling of the double-positive GFP+ SPC+ cell population in knockout (n =
9mice) compared with wild-typemice treated with tamoxifen (n = 16 mice) 72 h
after injury. Graph represents means with SEM. *P < 0.05.





















Genetic Deletion of Abl1 Promotes Expansion of SCGB1A1+ and SOX2+
Airway Cells That Coexpress SPC Following Pathogen-Induced Injury.
To characterize the specific cell types responsible for the marked
expansion of SCGB1A1+ SPC+ cells into the damaged alveolar
epithelium in Abl1-deficient mice, we employed three different
mouse models: (i) CC10 (Scgb1a1)-CreERT; Rosa26-fGFP, (ii)
SPC (Sftpc)-CreERT2; Rosa26-tdTomato, and (iii) SOX2-eGFP
mice. Prior studies identified a small pool (<1 cell per BADJ)
of SCGB1A1+ SPC+ putative bronchioalveolar stem cells within
the BADJ as a potential cell type of origin for type II AECs (17).
Consistent with previous reports, we found that after pathogen-
induced injury, wild-type mice displayed an increase in the number
of SPC+ cells that were also GFP+ around the BADJ (Fig. 3).
However, the number of GFP+ SPC+ cells markedly increased
from <5% up to ∼50% in the Abl1fl/fl mice after pathogen expo-
sure (Fig. 3). The profound increase in the SCGB1A1+ SPC+ cell
population in Abl1 knockout mice is unlikely to derive from the
limited pool of resident double-positive SCGB1A1+ SPC+ cells
within the BADJ alone.
To examine whether Abl1 inactivation in SCGB1A1+ cells af-
fected their proliferation, we performed immunofluorescence
staining for the Ki67 proliferation marker. A significant increase in
proliferating SCGB1A1+ cells was observed in bronchioles of
Abl1fl/fl mice compared with wild-type mice, with a maximal in-
crease occurring at 4 h after injury (Fig. 5 A and B and SI Appendix,
Fig. S7 A and B). These findings demonstrate that inactivation of
Abl1 in SCGB1A1+ cells elicits an early wave of cell proliferation
(∼4 h) following pathogen exposure that is not detected in
wild-type controls, which show increased proliferation at 24 h
postinjury compared with uninjured mice (SI Appendix, Fig. S7
A and B).
Next, we evaluated whether inactivation of Abl1 in SCGB1A1+
cells affected their differentiation. Costaining for GFP and SPC
followed by immunofluorescence microscopy revealed a signifi-
cant increase in expression of SPC within the bronchiolar secre-
tory cell population of Abl1 knockout compared with wild-type
control mice by day 3 following injury (Fig. 5C). In the absence of
injury, SPC expression is specific to type II AECs and is not de-
tected in the bronchiolar epithelium. To determine whether Abl1
inactivation elicited an increase in the expression of other type II
AEC markers, we performed FACS of GFP+ cells from lungs
of CC10 (Scgb1a1)-CreERT; Rosa26-fGFP; Abl1wt and Abl1fl/fl mice.
RT-qPCR analysis of lysates from the isolated GFP+ cells revealed
up-regulation of four of the most highly expressed genes in
type II alveolar cells (Sftpa, Sftpc, Lamp3, and ETV5) (40) in
Abl1 knockout compared with wild-type mice (Fig. 5D). To ob-
tain a functional readout of altered gene transcription induced
by Abl1 inactivation, we employed the translating ribosome af-
finity purification (TRAP) technique (41) using lungs from CC10
(Scgb1a1)-CreERT; L10a-eGFP; Abl1fl/fl and corresponding wild-type,
control mice. RT-qPCR showed an increase in actively translated
Sftpc mRNA that was pulled down from GFP-labeled ribosomes
in Abl1 knockout compared with wild-type mice (Fig. 5E). These
data show that Abl1 inactivation in a large population of SCGB1A1+
cells within the bronchioles elicits an early wave of enhanced
proliferation at 4 h after alveolar epithelial damage, followed by a
wave of differentiation 24 to 72 h after injury.
Fig. 4. Treatment with an Abl kinase inhibitor reverses lung injury following nasal insufflation of S. aureus. (A) Timeline of experiment: CC10 (Scgb1a1)-
CreER; Rosa26-fGFP mice were treated with an Abl kinase inhibitor or vehicle control b.i.d. starting 1 h after nasal insufflation of S. aureus. Mice were
evaluated 4, 24, and 72 h after injury. (B) Movement tracings of a 30-s video (Movie S2) of vehicle- and GNF5-treated mice 24 h after induction showing faster
recovery in mice treated with GNF5. (C) H&E staining of the left lung of vehicle- and GNF5-treated mice 3 d after injury. (A composite of images of mouse left
lung sections using a 10× objective on the Zeiss AxioImager microscope stitched together with Zen software to recreate the entire left lung.) (D) Quantifi-
cation of lung injury in H&E sections in vehicle- and GNF5-treated mice. (E and F) Bronchioalveolar lavage performed 3 d after injury shows (E) a reduction in
protein in the airspace in mice treated with GNF5 starting 24 h before injury (Pre) or 24 h after injury (Post) compared with control mice and (F) a reduction in
protein in the airspace in mice treated with nilotinib or GNF5 24 h after injury compared with control mice. (G) Three days after injury, mice treated with GNF5
(Right) demonstrated an increase in the GFP+ cell population in the alveolar epithelium compared with vehicle-treated mice (Left). (H) Costaining for GFP and
SPC antibodies showed an induction of SPC expression, a marker for type II AECs, in both the GFP+ cells of the bronchiolar and alveolar epithelium in GNF5-
treated mice. (I) Quantification of the percentage of SPC+ cells from the entire left lung that were also GFP+ in mice with genetic inactivation or phar-
macological inhibition of Abl kinases compared with control mice. (J) Immunofluorescence staining for the type I AEC marker RAGE 3 d after injury shows
widespread damage to the alveolar epithelium (dotted yellow lines) in untreated mice that is resolved in mice treated with GNF5. Graphs depict means and
SEM of n mice, where n represents each individual animal used (i.e., n = 6 represents six individual mice). *P < 0.05, **P < 0.01, and ***P < 0.001.




























To determine whether Abl kinase inhibition specifically in
type II alveolar epithelial cells contributes to the observed re-
generative phenotype in mice after injury, we used SPC (Sftpc)-
CreERT2; Rosa26-tdTomato mice (37) that were Abl1wt or
Abl1fl/fl. After exposure to S. aureus, damage to the lung alveo-
lar epithelium was detected in untreated SPC (Sftpc)-CreERT2;
Rosa26-tdTomato; Ablwt and Abl1fl/fl mice compared with SPC
(Sftpc)-CreERT2; Rosa26-tdTomato mice treated with the Abl ki-
nase inhibitor GNF5 (SI Appendix, Fig. S8 A and B). Notably,
we detected tdTomato+, RAGE+ (type I) cells derived from
tdTomato+, SPC+, RAGE− (type II) cells at sites of damage only
in mice treated with GNF5 3 d after injury (SI Appendix, Fig. S8C).
While it has been well-established that type II AECs contribute to
type I AEC regeneration after injury, our findings are consistent
with published data that, in wild-type mice, type I AECs lineage-
derived from type II AECs are only observed 5 to 7 d after injury
(16, 42). These data suggest that knockout of Abl1 in type II AECs
(SPC-CreERT2 model) alone is unlikely to contribute to the
accelerated regeneration of type I AECs observed 72 h after
knockout of Abl1 in Scgb1a1+ cells (CC10-CreERT model).
To further ascertain whether the expansion of SCGB1A1+
SPC+ cells arises from the bronchioles and BADJ versus
the small fraction (∼10%) of SCGB1A1+ type II AECs (12), we
employed a SOX2eGFP knockin/knockout mouse model (43).
Within the lung, SOX2 is expressed specifically in airway cells
but not in alveolar cells (44). Experiments performed in het-
erozygous mice in which the ORF of SOX2 is replaced by eGFP
allow for identification of cells actively expressing SOX2, and not
just lineage-derived cells from the airway cell population. Re-
markably, we found a dramatic increase in the proportion of
SOX2+ SPC+ cells expanding from the bronchioles into the lung
parenchyma in mice treated with the Abl kinase allosteric in-
hibitor GNF5 compared with vehicle control-treated mice (Fig.
6). Thus, Abl kinase inhibition promotes expansion of airway
cells that coexpresses SPC following injury.
Taken together, data from these three different mouse models
suggest that inactivation of Abl kinases specifically in SCGB1A1+
and SOX2+ airway epithelial cells, but not type II AECs, leads to
expansion of double-positive SCGB1A1+ SPC+ or SOX2+ SPC+
cell populations that precede regeneration of the damaged alveolar
epithelium following injury.
Mobilization of SCGB1A1+ SPC+ Cells to Sites of Injury Promotes
Alveolar Regeneration. To track the mobilization of the double-
positive SCGB1A1+ SPC+ cell population during regeneration
Fig. 5. Genetic inactivation of Abl1 promotes proliferation and differentiation
of Scgb1a1+ cells following injury. CC10 (Scgb1a1)-CreER; Rosa26-fGFP; Abl1wt
or Abl1fl/fl mice were given tamoxifen four times 2 wk before nasal insufflation
of S. aureus to induce excision of Abl1 and/or expression of GFP in Scgb1a1+
cells. (A) Four hours after exposure to S. aureus, GFP+ cells in knockout mice
exhibited increased rates of proliferation as measured by Ki67 staining com-
pared with wild-type mice. (Scale bars, 40 μm.) (B) Quantification. (C) Costaining
for GFP and SPC showed a significant increase in expression of SPC within the
bronchiolar secretory cell population of Abl1 knockout mice compared with
wild-type mice. (Scale bars, 100 μm.) (D) GFP+ cells were isolated from the lungs
of CC10 (Scgb1a1)-CreER; Rosa26-fGFP mice by FACS. RT-PCR of lysates from
isolated cells showed a significant increase in expression of four genes highly
expressed in type II cells in knockout mice compared with wild-type mice (n =
4 mice per group). (E) RT-PCR quantification of Sftpc mRNA expression from
CC10 (Scgb1a1)-CreER; L10a-eGFP mice showing an increase in actively trans-
lated Sftpc mRNA pulled down from GFP-labeled ribosomes in knockout mice
compared with wild-type control mice (n = 3 mice per group). Graphs represent
means with SEM. *P < 0.05.
Fig. 6. Inhibition of Abl1 promotes expansion of the SOX2+ SPC+ cell
population in mouse lungs following injury. SOX2eGFP mice were pretreated
with vehicle or the Abl kinase inhibitor GNF5 (100 mg/kg, b.i.d. via oral
gavage) 24 h before nasal insufflation of S. aureus. Three days after injury,
lungs were harvested, paraffin-embedded, sectioned, and stained with an-
tibodies to GFP and SPC. (A) Immunofluorescence staining showed a signif-
icant increase in the number of double-positive GFP+ SPC+ cells in GNF5-
treated mice compared with vehicle-treated mice 72 h after injury. (Scale
bars, 50 μm.) (B) Quantification of the proportion of double-positive cells
was performed over 5-μm sections of the entire left lungs of mice (n = 5 mice
per group). *P < 0.05. Bar graphs represent means with SEs of measurement.





















of the alveolar epithelium, we performed immunofluorescence
staining for GFP (Scgb1a1 driver), SPC (type II AEC marker),
and RAGE (type I AEC marker) proteins in wild-type and
Abl1 knockout mice at various times after exposure to S. aureus.
In wild-type mice, we found an increase in the number of SPC+
but GFP− type II AECs at sites of injury in the alveolar epithelium
at day 3 postinfection (Fig. 7A, Top). By contrast, Abl1 knockout
in CC10 (Scgb1a1)-CreERT; Rosa26-fGFP; Abl1fl/fl mice exposed
to S. aureus displayed increased numbers of GFP+ (Scgb1a1
driver) SPC+ cells at sites of alveolar repair following damage
(Fig. 7A, Bottom). The architecture of the damaged alveolar epi-
thelium was largely restored (as evaluated by immunostaining for
RAGE) in the Abl1 knockout mice by day 3 postinfection with
areas of hypercellularity and decreased alveolar volume, sugges-
tive of damaged epithelium undergoing repair. In Abl1 knockout
mice, GFP+ (Scgb1a1 driver) SPC+ cells expand from the bron-
chioles and/or BADJ to sites of damage, which precedes enhanced
alveolar epithelial cell regeneration, and these phenotypes are not
observed in wild-type mice (Fig. 7 B and C).
To evaluate whether SCGB1A1+ SPC+ cells promote alveolar
epithelium regeneration directly by differentiating into type I
AECs, mouse lung sections were stained at various times fol-
lowing injury to detect the presence of triple-positive GFP+
(Scgb1a1 driver), RAGE+, SPC+ versus GFP+, RAGE+ but
SPC− cells at sites of injury. Small clusters of triple-positive cells
as well as GFP+ (Scgb1a1 driver) RAGE+ cells were detected in
lung sections of both wild-type and Abl1 knockout mice 30 d fol-
lowing injury but not at earlier time points (SI Appendix, Fig. S9).
Because Abl1 knockout mice exhibited accelerated recovery from
infection 24 to 72 h after injury, it is unlikely that differentiation of
GFP+ (Scgb1a1 driver) SPC+ cells into GFP+RAGE+ cells at day
30 postinjury significantly contributed to the observed early alve-
olar regeneration phenotypes. It is more likely that double-positive
SCGB1A1+ SPC+ cells mobilize to sites of injury and promote
local type II AECs to regenerate type I AECs, leading to repair of
the damaged lung epithelium (model, Fig. 7D). Consistent with this
possibility is the observation that SPC (Sftpc)-CreERT2; Rosa26-
tdTomato mice treated with GNF5 displayed an increase in the
proportion of tdTomato+ (Sftpc driver) RAGE+ type I AECs
compared with untreated wild-type and Abl1 knockout mice in
SPC+ type II AECs (SI Appendix, Fig. S8).
Loss of Abl1 in SCGB1A1+ Lung Epithelial Cells Promotes Recovery in
Mice Following S. pneumoniae-Induced Injury. To assess whether
conditional knockout of Abl1 promoted lung epithelial regenera-
tion in mice following exposure to other pathogens, we used
S. pneumoniae. We evaluated recovery in wild-type and Abl1
knockout mice following nasal insufflation of S. pneumoniae (45),
a more virulent bacterial strain than the strain of S. aureus used.
We found that while both wild-type and Abl1 conditional knock-
out mice (Scgb1a1 driver) lost the same amount of body weight
within 12 h after injury, the Abl1 knockout mice recovered body
weight more quickly compared with wild-type, control mice (SI
Appendix, Fig. S10A). Consistent with these findings, we found
decreased damage to the lung parenchyma, as measured by an
increase in average alveolar area/volume, in Abl1 knockout
compared with wild-type mice (SI Appendix, Fig. S10B). We also
found a significant increase in the proportion of GFP+ (Scgb1a1
driver) SPC+ cells in Abl1 knockout versus wild-type mice. In-
terestingly, in the S. pneumoniae injury model, we found a dra-
matic expansion of the double-positive cells as early as 6 h after
injury (SI Appendix, Fig. S10 C and D). Thus, data from both S.
aureus- and S. pneumoniae-induced injury models demonstrate
that conditional knockout of Abl1 (Scgb1a1 driver) leads to ex-
pansion of a subpopulation of SCGB1A1+ SPC+ cells, promotes
lung regeneration, and accelerates mouse recovery after injury.
Discussion
Respiratory pathologies are the third-leading cause of death in
the industrialized world and, with the emergence of resistant
bacterial strains, there is an urgent need to identify novel ther-
apies for use in combination with antibiotics and supportive care.
Here we identify the Abl kinases as a promising therapeutic
target to promote alveolar epithelial regeneration following lung
injury. Previous studies showed that distal lung epithelium, in-
cluding type I and type II AECs, can be derived from a pop-
ulation of SCGB1A1+ SPC+ cells. During lung development,
these cells have been identified as a putative cell type of origin
for both type I and type II AECs (40). There is evidence that a
rare population of these putative bronchioalveolar stem cells
exists in the adult lung and resides at the BADJ (17). Accord-
ingly, we found that in wild type- and/or vehicle control-treated
mice, normal regeneration of lung alveolar epithelium involves
expansion (from <5% to 10 to 15%) of a small pool (<1 cell per
BADJ) of SCGB1A1+ SPC+ cells originating at the BADJ, with
complete recovery taking about 1 wk. Another recent study
showed expansion of this population of cells 11 to 17 d after
bleomycin- or influenza-induced lung injury (46). Surprisingly,
we found that genetic or pharmacological inactivation of Abl
kinases promotes a dramatic expansion (<5% to 25 to 50%) of
airway cells positive for Scgb1a1 or SOX2 that coexpress the SPC
type II alveolar marker by 24 h following S. aureus-induced injury
and as early as 6 h following S. pneumoniae-induced injury. Further,
Abl1 genetic inactivation specifically in Scgb1a1+-expressing
cells mobilizes a large pool of Scgb1a1+ cells from the bron-
chioles that are not appreciably involved in regeneration of the
alveolar epithelium in wild-type mice. We detected cell proliferation
within 4 h after pathogen-induced injury in Abl1-deficient mice,
followed by a wave of differentiation (24 to 72 h) of an expanded
pool of SCGB1A1+ secretory cells within the bronchiole, leading
to dramatic expansion of double-positive SCGB1A1+ SPC+ cells
at sites of injury, followed by enhanced alveolar regeneration
compared with wild-type mice. The rapid timeline of regeneration
observed in Abl1-deficient mice is relevant because S. aureus and
S. pneumoniae infections are associated with progression to sepsis
and multiorgan system failure, and early intervention is key in
reducing mortality in these patients. In fact, early antibiotic treat-
ment within the first 1 to 6 h is the only proven intervention to
reduce mortality, highlighting the importance of early intervention
(47, 48). We found no effect of Abl1 inactivation in SCGB1A1 cells
on immune cell responses and susceptibility to bacterial infec-
tion compared with wild-type mice. Both genetic and pharmaco-
logical inactivation of Abl kinases elicited rapid recovery follow-
ing pathogen-induced injury and enhanced regeneration of the
alveolar epithelium.
Genetic inactivation of Abl1 in Scgb1a1+ cells was found to
not only promote expansion of SCGB1A1+ SPC+ cells but also
to enhance regeneration of RAGE+ type I alveolar epithelium
within 3 d after injury. Our data suggest that inactivation of Abl
kinases promotes expansion of SCGB1A1+ SPC+ cells, which
indirectly leads to regeneration of type I AECs following injury.
The absence of GFP+ (Scgb1a1 driver) RAGE+ cells at day
3 post S. aureus-induced injury suggests that the double-positive
SCGB1A1+ SPC+ cells are not likely to directly differentiate
into type I AECs to regenerate the alveolar epithelium. While it
is not possible to rule out epigenetic silencing at the Rosa26 locus
as a potential mechanism for the loss of GFP expression in type I
AECs following differentiation, the fact that small clusters of
GFP+ RAGE+ cells were detected at day 30 suggested that
epigenetic silencing was unlikely the reason. It is more likely that
type I AEC regeneration occurs through the differentiation of
type II AECs locally at sites of injury induced by the expansion
and mobilization of SCGB1A1+ SPC+ cells. Alternatively, the
double-positive SCGB1A1+ SPC+ cells may function to activate




























Fig. 7. Scgb1a1+ SPC+ cells expand to sites of injury and promote regeneration. (A) Three days following exposure to S. aureus, CC10 (Scgb1a1)-CreER; Rosa26-
fGFP; Abl1wt mouse lungs (Top) exhibit large areas of alveolar epithelial damage shown by staining for the type I AEC marker RAGE. There is an accumulation of
type II AECs, indicated by staining for SPC, at sites of damage (purple dashed lines). Knockout mouse lungs (Bottom) exhibit regenerated alveolar epithelium with
regions of hypercellularity and reduced area of alveolar loss/volume. In areas of repair (purple dashed lines), a dramatic increase in double-positive GFP+ SPC+ cells
was observed. (Scale bars, 25 μm.) (B) Lower-magnification images of knockout (Right) mouse lungs 3 d after exposure to S. aureus demonstrate the enhanced
proliferation and differentiation of Scgb1a1+ cells to Scgb1a1+ SPC+ cells compared with wild-type (Left) mouse lungs. (Scale bars, 50 μm.) (C) Higher-magnification
images of cells expanded from the BADJ to sites of damage (boxes in B). (Scale bars, 20 μm.) (D) Model. Following injury to the alveolar epithelium, wild-type mice
(Left) initiate regeneration through expansion of a rare population of double-positive Scgb1a1+ (CC10+) SPC+ cells at the BADJ and local differentiation of type II
AECs. By contrast, knockout of Abl1 in Scgb1a1-expressing cells in the bronchioles and BADJ promotes proliferation and differentiation into double-positive
Scgb1a1+ SPC+ cells, which in turn mobilize to sites of injury to indirectly promote regeneration of type I AECs from resident type II AECs.





















stromal cells at sites of injury to promote regeneration of type I
AECS from type II alveolar cells. In this regard, signaling by
bone morphogenetic protein 4 was shown to regulate alveolar
progenitor cell proliferation and differentiation, in part by tar-
geting stromal cells in the alveolar stem cell niche (49).
The finding that inactivation of Abl kinases promotes re-
generation of the alveolar epithelium following pathogen-induced
injury uncovers a previously unappreciated deleterious role for
activation of Abl kinases following lung injury. The activity of Abl
kinases is required for normal mouse development, as genetic
inactivation of Abl1 results in perinatal lethality (18, 21). In-
hibition of Abl kinases with pharmacological agents in healthy
adult mice does not produce deleterious effects, thereby suggest-
ing that endogenous Abl kinases are not required for normal
cellular homeostasis in the adult (22). Abl kinases are hyperactive
in BCR-ABL–positive leukemia and some solid tumors, as well as
in response to inflammation, DNA damage, and oxidative stress,
and in various pathologies (19, 22, 27). Abl kinase inhibitors have
beneficial therapeutic effects for the treatment of human leuke-
mia, metastatic tumors in mice, as well as pathologies linked to
inflammation and neurodegeneration (19, 27, 29–31, 50). The
consequences of Abl activation for cell proliferation are cell
context-dependent. Whereas activation of the Abl kinases pro-
motes cell proliferation in leukemia cells, some solid tumors, and
multiple cell types stimulated with growth factors, Abl1 activation
is antiproliferative in the response to DNA damage (51), and
Abl2 negatively regulates myoblast proliferation in mice (52).
Abl kinases regulate various downstream targets, some of which
have been shown to play a role in the regulation of lung epithelial
cells following injury. These include transcriptional coactivators of
the Hippo (Yap1, Taz) and Wnt (β-catenin) signaling pathways,
both of which have been implicated in alveolar regeneration (53–
55). The Hippo pathway regulates organ development, and
Yap1 activation regulates mechanical tension-induced pulmonary
alveolar regeneration (55) as well as airway regeneration following
exposure to naphthalene (54). Functional interactions among
Abl1, Yap1, and Taz have been reported in development, cancer,
and the cellular response to damage. Activation of Abl1 in re-
sponse to DNA damage was reported to promote activation of a
proapoptotic program mediated by Yap1 (56). Abl kinases were
recently shown to regulate osteoblast differentiation and lung
adenocarcinoma metastasis by regulating stabilization of the Taz
transcriptional coactivator (50, 57). Previously, we reported that
Abl kinases regulate the Wnt-β-catenin pathway in lung cancer
cells (50). Wnt signaling was shown to regulate cell proliferation
and differentiation during alveologenesis (53). Future studies will
seek to identify the molecular targets downstream of activated Abl
kinases in lung epithelial cells that regulate cell proliferation and
differentiation pathways in response to injury induced by S. aureus
and other agents.
Our findings revealed that inactivation of Abl kinases pro-
motes lung epithelial cell regeneration in mouse models of
pneumonia induced by S. aureus and S. pneumoniae. The data
suggest that FDA-approved inhibitors for the treatment of BCR-
ABL+ leukemias might be repurposed for the treatment of lung
injury. In fact, several case reports have demonstrated that
treatment of leukemia patients with imatinib (which inhibits not
only ABL kinases but the PDGFR and other kinases) resulted in
resolution of pulmonary symptoms such as acute interstitial
pneumonia or drug-induced pneumonitis (58–62). Our studies
have focused on lung injury induced by S. pneumoniae and S.
aureus, which target the alveolar epithelium resulting in necro-
tizing pneumonias, and future studies are warranted to evaluate
whether inactivation of Abl kinases might be exploited as a
therapeutic strategy to promote lung regeneration in response to
injury induced by a variety of toxins and other pathogens. These
include destructive agents such as chlorine gas and influenza
virus, as well as nondestructive lung injury such as drug-induced
pneumonitis or atypical pneumonia. Our findings of regenera-
tion in mice with Abl-specific inactivation following pathogen-
induced injury, together with case reports of patients treated
with imatinib showing improved pulmonary function following
drug-induced pneumonitis, suggest that Abl inhibitors might be
used to promote repair and/or regeneration of the lung in a wide
variety of lung pathologies.
Materials and Methods
Additional experimental details are provided in SI Appendix, including
bacteria and reagents used, as well as procedures for real-time PCR analysis,
immunoblotting, bronchioalveolar lavage, immunohistochemistry, immu-
nofluorescence, FACS, and mouse experiments.
Cell Culture. Primary human bronchial epithelial cells were isolated from
normal donors as previously described (36), and were provided by the Uni-
versity of North Carolina at Chapel Hill Cystic Fibrosis Center Tissue Pro-
curement and Cell Culture Core. Passage 1 cells were derived from human
lungs unsuitable for transplantation from nonsmoker organ donors without
preexisting lung disease under protocol 03-1396 approved by the University of
North Carolina at Chapel Hill Biomedical Institutional Review Board. Informed
consent was obtained from authorized representatives of all organ donors.
Mice. CC10 (Scgb1a1)-CreERT; Rosa26R-CAG-farnesylated GFP (Rosa26-fGFP)
and SPC (Sftpc)-CreERT2; Rosa26-tdTomato mice were provided by Mark
Onaitis, University of California, San Diego, La Jolla, CA and generated by
Brigid Hogan at Duke University and have been previously described (12, 37).
These mice were crossed with Abl1flox/flox mice (63) into a C57BL/6 genetic
background. Sox2tmHoch/J mice (referred to as SOX2-eGFP mice) were pur-
chased from the Jackson Laboratory. Gt(Rosa)26Sortm9(EGFP/Rpl10z)Amc/J (re-
ferred to as L10-eGFP) mice were purchased from the Jackson Laboratory
and crossed to CC10-CreERT; Abl1flox/flox mice into a C57BL/6 background
for the TRAP experiments. To induce expression of Cre-recombinase, 8- to
20-wk-old male and female mice were injected intraperitoneally four times
every other day with 0.25 mg/g body weight tamoxifen (Sigma; T5648) in
corn oil (Spectrum; CO136). Exposure to S. aureuswas initiated 15 d after the
last dose of tamoxifen. All experiments were performed under Duke Uni-
versity Institutional Animal Care and Use Committee-approved protocols
A098-16-04 and A130-16-06. Additional experimental details are provided in
SI Appendix.
Statistical Analysis. The number of animals in each group is indicated in the
figures and/or figure legends. Differences among groups for immunofluo-
rescence and H&E experiments were assessed using one-way ANOVA fol-
lowed by post hoc Tukey tests. All quantification for these experiments was
performed using stitched images for the entire left lung (>100,000 cells
counted per image). Representative high-resolution images from each ani-
mal group are indicated in the figures. Results are presented as means ± SE
of measurement. BAL experiments were analyzed using a repeated-measure
multivariate analysis of variance (MANOVA) followed by post hoc Fisher’s
protected least significant difference testing to account for difference in
variance between cell count, protein, and LDH data collected from each
animal. Individual group testing was performed only when statistical sig-
nificance was achieved from the ANOVA and MANOVA. All quantification
for these experiments was performed using fluid from both the right and
left lungs from each animal. For the human bronchial epithelial cell exper-
iments, cells from three nonsmoker donors were used. Real-time RT-qPCR
experiments were all performed in duplicate or triplicate in two or three
separate mice or human patient samples. *, **, and *** indicate P values,
<0.05, <0.01, and <0.001, respectively. Bar graphs represent means with
SEs of measurement.
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